FI971275A - Bristfälliga rekombinat adenovirus med inaktiverad IVa2-gen - Google Patents

Bristfälliga rekombinat adenovirus med inaktiverad IVa2-gen Download PDF

Info

Publication number
FI971275A
FI971275A FI971275A FI971275A FI971275A FI 971275 A FI971275 A FI 971275A FI 971275 A FI971275 A FI 971275A FI 971275 A FI971275 A FI 971275A FI 971275 A FI971275 A FI 971275A
Authority
FI
Finland
Prior art keywords
inactivated
recombinant adenoviruses
iva2 gene
incomplete
gene
Prior art date
Application number
FI971275A
Other languages
English (en)
Finnish (fi)
Other versions
FI971275A0 (sv
Inventor
Cecile Orsini
Michel Perricaudet
Emmanuelle Vigne
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI971275A0 publication Critical patent/FI971275A0/sv
Publication of FI971275A publication Critical patent/FI971275A/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI971275A 1994-09-27 1997-03-26 Bristfälliga rekombinat adenovirus med inaktiverad IVa2-gen FI971275A (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9411511A FR2724945B1 (fr) 1994-09-27 1994-09-27 Vecteurs viraux et utilisation en therapie genique
PCT/FR1995/001228 WO1996010088A1 (fr) 1994-09-27 1995-09-22 ADENOVIRUS RECOMBINANTS DEFECTIFS AVEC UN GENE IVa2 INACTIVE

Publications (2)

Publication Number Publication Date
FI971275A0 FI971275A0 (sv) 1997-03-26
FI971275A true FI971275A (sv) 1997-03-26

Family

ID=9467310

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971275A FI971275A (sv) 1994-09-27 1997-03-26 Bristfälliga rekombinat adenovirus med inaktiverad IVa2-gen

Country Status (18)

Country Link
US (1) US6200798B1 (sv)
EP (1) EP0783585B1 (sv)
JP (1) JPH10506018A (sv)
KR (1) KR100484441B1 (sv)
AT (1) ATE331801T1 (sv)
AU (1) AU712304B2 (sv)
CA (1) CA2197904A1 (sv)
DE (1) DE69535093T2 (sv)
DK (1) DK0783585T3 (sv)
ES (1) ES2268695T3 (sv)
FI (1) FI971275A (sv)
FR (1) FR2724945B1 (sv)
IL (1) IL115432A (sv)
MX (1) MX9701766A (sv)
NO (1) NO319055B1 (sv)
PT (1) PT783585E (sv)
WO (1) WO1996010088A1 (sv)
ZA (1) ZA958128B (sv)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738852A (en) * 1993-04-20 1998-04-14 Solis Therapeutics, Inc. Methods of enhancing antigen-specific T cell responses
WO1996018418A1 (en) * 1994-12-12 1996-06-20 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
AU1288099A (en) 1997-10-30 1999-05-24 Cornell Research Foundation Inc. A method of inhibiting an immune response to a recombinant vector
IL141403A0 (en) * 1998-08-28 2002-03-10 Univ Duke Deleted adenoviruses and methods of making and administering the same
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
EP1539937A4 (en) * 2002-08-22 2006-07-26 Merck & Co Inc METHODS OF PROPAGATION OF ADENOVIRUS AND VIRUS SO OBTAINED
US10000757B2 (en) 2005-05-27 2018-06-19 Ospedale San Raffaele S.R.L. Gene vector

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.

Also Published As

Publication number Publication date
DK0783585T3 (da) 2006-10-23
NO971247L (no) 1997-03-18
AU3525095A (en) 1996-04-19
FR2724945A1 (fr) 1996-03-29
JPH10506018A (ja) 1998-06-16
PT783585E (pt) 2006-11-30
IL115432A0 (en) 1996-01-31
FR2724945B1 (fr) 1996-12-27
EP0783585B1 (fr) 2006-06-28
WO1996010088A1 (fr) 1996-04-04
DE69535093D1 (de) 2006-08-10
NO319055B1 (no) 2005-06-13
MX9701766A (es) 1997-06-28
DE69535093T2 (de) 2007-01-04
FI971275A0 (sv) 1997-03-26
CA2197904A1 (fr) 1996-04-04
US6200798B1 (en) 2001-03-13
EP0783585A1 (fr) 1997-07-16
ES2268695T3 (es) 2007-03-16
KR100484441B1 (ko) 2006-01-27
IL115432A (en) 2006-10-05
AU712304B2 (en) 1999-11-04
ZA958128B (en) 1996-04-24
NO971247D0 (no) 1997-03-18
KR970706397A (ko) 1997-11-03
ATE331801T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
FI951138A0 (sv) Defekta adenovirusvektor och användning av dessa inom genterapi
MX9603002A (es) Procedimiento para la preparacion de virus asociados a los adenovirus (aav), recombinantes, y usos de los mismos.
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
ES2191663T3 (es) Virus recombinante de la viruela porcina.
HUP9802217A3 (en) Recombinant mva virus, and the use thereof
FR2716893B1 (fr) Virus recombinants, leur préparation et leur utilisation thérapeutique.
DE69534778D1 (en) Cathepsin-02-protease
FI964592A0 (sv) Papillomavirusvacciner
FI971275A (sv) Bristfälliga rekombinat adenovirus med inaktiverad IVa2-gen
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
DE69636453D1 (de) Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp)
IL181695A0 (en) Methods for cultivating cells and propagating viruses
BR9607583B1 (pt) plasmìdios procarióticos recombinantes.
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
KR970702919A (ko) 재조합형의 인간면역부전바이러스 담체 및 그 제조방법(Recombinant Human Immunodeficiency Virus Vector and Process for Producing the same)
MX9702078A (es) Adenovirus que comprenden dos genes terapeuticos: suicida e inmunoestimulante.
DE69726602D1 (en) Hepatitis b inhibitoren
AU2176997A (en) Novel fused protein, gene therefor, recombinant vector, recombinant virus, and its use
FR2720756B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA2475337A1 (en) Methods for cultivating cells and propagating viruses
FR2717497B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2718749B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
MX9709514A (es) Viruses de fowlpox recombinantes y usos de los mismos.